Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Open accessThe DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is characterized by a deficit in β-cell mass, impaired insulin secretion in response to various stimuli (1–3), as well as a variable extent of insulin resistance (4). More specifically, regarding β-cell function, a significant reduction of the incretin effect, i.e., the postprandial augmentation of insulin secretion by gut hormones, has been described in patients with type 2 diabetes (5). Thus, while the two incretin hormones gastric inhibitory polypeptide (glucose-dependent insulinotopic polypeptide [GIP]) and glucagon-like peptide 1 (GLP-1) are held responsible for ∼50–70% of the postprandial insulin responses in healthy individuals (6), their contribution to the overall insulin responses after oral glucose ingestion may amount to <20% in patients with type 2 diabetes (5,7). The reasons underlying the loss of incretin activity in type 2 diabetes are still incompletely understood. The present article reviews the available evidence regarding disturbances in the enteroinsular axis in patients with type 2 diabetes and provides possible explanations for their etiologies, focusing on the personal experience of the authors. ### Secretion of incretin hormones in patients with type 2 diabetes. Because the incretin effect has been related to the secretion and insulinotropic action of GIP and GLP-1 (8,9), it was obvious to compare these parameters between patients with type 2 diabetes and healthy control subjects: Regarding the secretion of GIP, elevated, normal, and reduced plasma levels have been described in patients with type 2 diabetes (10–15). However, taking together all the evidence available, the secretion of GIP appears to be relatively unchanged in type 2 diabetic patients. For GLP-1 release, the case is even more complex. Several studies have reported significant reductions in GLP-1 levels after mixed meal ingestion in patients with type 2 diabetes (10,16,17). In addition, one study has found minor impairments in GLP-1 levels in individuals with impaired glucose …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The current consensus in the literature is that GLP-1 and GIP circulation levels are comparable between T2D patients and nondiabetic controls in response to nutrient challenges.158”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“The diminished incretin effect in patients with type 2 diabetes was described more than 20 years ago (5), but even now the underlying causes remain elusive.”
BackgroundSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“By these means, the hyperglycemia in patients with type 2 diabetes can readily be normalized by the intravenous administration of GLP-1 (26), even at relatively low doses (27).”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 2×
“The incretin effect is defined by the differences in the insulin secretory responses elicited by oral glucose administration and intravenous glucose infusion (6,8).”
BackgroundSelf-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Research works printed but not linked: 5
- Meier, 2005, Insulin secretion, 961
- Ebert, 1980, Hypo- and hypersecretion of GIP in maturity-onset diabetics (Abstract), Diabetologia, 19, 271
- Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes, Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
- Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
- Pfeifer, 1981, Insulin secretion in diabetes mellitus, Am J Med, 70, 579, 10.1016/0002-9343(81)90579-9 · DOI · Paper page
Cited by
Items 101–200 of 215
Frost, F. J., Jones, G. H., Dyce, P., Jackson, V., Nazareth, D. S., & Walshaw, M. J. (2019) · Diabetic Medicine · doi:10.1111/dme.14121 · Cited by 25
Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus
Kosiński, M., Knop, F. K., Vedtofte, L., Grycewiczv, J., Swierzewska, P., Cypryk, K., & Vilsbøll, T. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.08.002 · Cited by 25
Ceriello, A., Novials, A., Ortega, E., Canivell, S., Pujadas, G., Sala, L. L., Bucciarelli, L. G., Rondinelli, M., & Genovese, S. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-97 · Cited by 24
New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs
Gilor, C., Rudinsky, A. J., & Hall, M. J. (2016) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x16660441 · Cited by 26
Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis
Grespan, E., Guolo, A., Muscelli, E., Ferrannini, E., & Mari, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac213 · Cited by 24
Zhang, S., Wang, S., Puhl, M. D., Jiang, X., Hyrc, K. L., Laciny, E., Wallendorf, M., Pappan, K. L., Coyle, J. T., & Wice, B. M. (2014) · Diabetes · doi:10.2337/db14-1188 · Cited by 21
Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins
Ríos, J.-L., Andújar, I., Schinella, G. R., & Francini, F. (2019) · Planta Medica · doi:10.1055/a-0897-7492 · Cited by 21
Nauck, M. A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154031 · Cited by 22
Self-citationGluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
Vallois, D., Niederhäuser, G., Ibberson, M. R., Nagaray, V., Marselli, L., Marchetti, P., Chatton, J., & Thorens, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103277 · Cited by 21
Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice
He, L., Law, P. T. Y., Wong, C. K., Chan, J. C. N., & Chan, P. K. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-01952-5 · Cited by 20
All-encomPASsing regulation of β-cells: PAS domain proteins in β-cell dysfunction and diabetes
Sabatini, P. V., & Lynn, F. C. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.11.002 · Cited by 24
Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
Okawa, T., Kamiya, H., Himeno, T., Seino, Y., Tsunekawa, S., Hayashi, Y., Harada, N., Yamada, Y., Inagaki, N., Seino, Y., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12129 · Cited by 18
Kampmann, K., Ueberberg, S., Menge, B. A., Breuer, T. G. K., Uhl, W. H., Tannapfel, A., & Meier, J. J. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.025 · Cited by 21
Self-citationIncretins and the intensivist: what are they and what does an intensivist need to know about them?
Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 18
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Toth, P. P. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2303 · Cited by 17
Oh, T. J., Shin, J. Y., Kang, G. H., Park, K. S., & Cho, Y. M. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.58 · Cited by 13
Exposure to bisphenol a and risk of developing type 2 diabetes: A mini review
Siddique, S., Zhang, G., & Kubwabo, C. (2020) · Emerging contaminants · doi:10.1016/j.emcon.2020.07.005 · Cited by 16
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_13 · Cited by 15
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
Rieger, T. R., & Musante, C. J. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.006 · Cited by 10
Incretins today: multiple effects and therapeutic potential
Васильевна, Ц. О., Васильевна, В. В., & As, A. (2019) · Diabetes Mellitus · doi:10.14341/dm9841 · Cited by 22
Lipotoxicity impairs incretin signalling
Poitout, V. (2012) · Diabetologia · doi:10.1007/s00125-012-2788-6 · Cited by 14
Okada, K., Yagyu, H., Kotani, K., Yamazaki, H., Ozaki, K., Takahashi, M., Nagashima, S., Osuga, J.-I., & Ishibashi, S. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0019 · Cited by 11
GLP-1 signaling and the regulation of pancreatic β-cells mass/function
Buteau, J. (2011) · Avances en Diabetología · doi:10.1016/s1134-3230(11)70002-3 · Cited by 14
The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers
Nielsen, S. T., Harder-Lauridsen, N. M., Benatti, F. B., Wedell‐Neergaard, A., Lyngbæk, M. P. P., Møller, K., Pedersen, B. K., & Krogh‐Madsen, R. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00821.2015 · Cited by 10
Ekholm, E., Shaat, N., & Holst, J. J. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0312-y · Cited by 13
Emerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. P. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 10
Aizawa, T., Yamada, M., Katakura, M., Funase, Y., Yamashita, K., & Yamauchi, K. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0162 · Cited by 9
Grunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12046 · Cited by 8
Kawaguchi, Y., Hajika, Y., Rinka, M., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14151 · Cited by 13
Glucose Metabolism in Critically Ill Patients: Are Incretins an Important Player?
Nielsen, S. T., Krogh‐Madsen, R., & Møller, K. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613503291 · Cited by 9
Kawaguchi, Y., Miyamoto, S., Hajika, Y., Ashida, N., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13677 · Cited by 8
Tarigan, T. J. E., Purwaningsih, E. H., Yusra, Y., Abdullah, M., Nafrialdi, N., Prihartono, J., Saraswati, M. R., & Subekti, I. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1535703 · Cited by 11
Association of GLP1R Polymorphisms With the Incretin Response
Dorsey-Treviño, E. G., Kaur, V., Mercader, J. M., Florez, J. C., & Leong, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac374 · Cited by 10
Pharmacogenetics of insulin secretagogue antidiabetics
Winkler, G., & Gerő, L. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29175 · Cited by 8
Roussel, M., Mathieu, J., & Dalle, S. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0071 · Cited by 11
Tanabe, A., Kaneto, H., Kamei, S., Hirukawa, H., Shimoda, M., Kimura, T., Obata, A., Okauchi, S., Tatsumi, F., Kohara, K., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.005 · Cited by 7
New avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Hu, Y., Zhang, P., Ding, B., Cao, X., Zhong, Y., Sun, Y.-X., Lee, K.-O., & Ma, J. (2022) · Nutrition and Diabetes · doi:10.1038/s41387-022-00208-0 · Cited by 7
Chaiyakul, S., Ketkham, N., Chaichana, C., Khumkhana, N., Deekum, W., Wongshaya, P., Suwanmalai, T., Hutchinson, C., & Pramyothin, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1141497 · Cited by 7
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_9 · Cited by 10
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., & Fonseca, V. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-1 · Cited by 10
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-2 · Cited by 11
Incretin Hormones and the Up-Regulation of Insulin Secretion in Insulin Resistance
Åhrén, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1420 · Cited by 7
Athauda, D. S., Evans, J. R., Mahoney‐Sanchez, L., Virdi, G. S., Lopez-Garcia, P., Wernick, A. I., Wagen, A. Z., D’Sa, K., Lachica, J., Strohbuecker, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582460 · Cited by 8
Rakha, A., Rasheed, H., Altemimi, A. B., Tul‐Muntaha, S., Fatima, I., Butt, M. S., Hussain, S., Bhat, Z. F., Khaneghah, A. M., & Aadil, R. M. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104195 · Cited by 7
Puddu, A., Sanguineti, R., Montecucco, F., & Viviani, G. L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/326359 · Cited by 7
Linagliptin for the treatment of Type 2 diabetes
Tella, S. H., Aktürk, H. K., & Rendell, M. (2013) · Diabetes Management · doi:10.2217/dmt.13.55 · Cited by 6
Horie, I., Haraguchi, A., Sako, A., Akeshima, J., Niri, T., Shigeno, R., Ito, A., Nozaki, A., Natsuda, S., Akazawa, S., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.08.015 · Cited by 6
Oh, T. J., Park, K. S., & Cho, Y. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12623 · Cited by 6
In Vivo Models for Incretin Research: From the Intestine to the Whole Body
Oh, T. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.45 · Cited by 8
Cho, K. Y., Nomoto, H., Nakamura, A., Kawata, S., Sugawara, H., Takeuchi, J., Nagai, S., Omori, K., Tsuchida, K., Miya, A., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13498 · Cited by 5
Sakornyutthadej, N., Mahachoklertwattana, P., Chanprasertyothin, S., Pongratanakul, S., Khlairit, P., & Poomthavorn, P. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13303 · Cited by 5
Khaliq, A., Chughtai, M. F. J., Iqbal, J., Nawaz, H., Ahsan, S., Mehmood, T., Liaqat, A., Nadeem, M., Sameed, N., Saeed, K., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-76320-6_16 · Cited by 4
Hupfeld, C. J., & Olefsky, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00040-8 · Cited by 9
Nauck, M. A., & Meier, J. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch48 · Cited by 4
Self-citationPathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_8 · Cited by 4
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
Wibawa, I. D. N., Mariadi, I. K., Somayana, G., Kumbara, C. I. Y. K., & Sindhughosa, D. A. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.549 · Cited by 4
Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01412-8 · Cited by 3
Hamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Suzuki, K., & Inagaki, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1301352 · Cited by 3
Choi, K., Lee, J. C., Oh, T. J., Kim, M., Kim, H. C., Cho, Y. M., & Kim, S. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2465156 · Cited by 3
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
β-Hydroxypyruvate: A New Diabetogenic Factor?
Mizuno, T. M. (2015) · Diabetes · doi:10.2337/db14-1830 · Cited by 3
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
Self-citationTura, A., Göbl, C. S., El‐Tanani, M., & Rizzo, M. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1452400 · Cited by 3
Otterbeck, P. E., & Banerji, M. A. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.6 · Cited by 1
Deacon, C. F. (2012) · Diabetes · doi:10.2337/db12-0649 · Cited by 2
Significance of Organ Crosstalk in Insulin Resistance and Type 2 Diabetes
Bhatt, S., & Kulkarni, R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415784-2.00017-8 · Cited by 3
He, T., Geng, J., & Zhang, Z. (2017) · Translational medicine research · doi:10.1007/978-981-10-5804-2_9 · Cited by 3
Shimoda, M., Miyoshi-Takai, M., Irie, S., Tanabe, A., Obata, A., Okauchi, S., Hirukawa, H., Kimura, T., Kohara, K., Kamei, S., et al. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5856475 · Cited by 2
The incretin effect in type 2 diabetes in a Sub-Saharan African population
Nielsen, S. T., Kweka, B. V., PrayGod, G., Filteau, S., Olsen, M. F., Friis, H., Faurholt‐Jepsen, D., & Krogh‐Madsen, R. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00178-5 · Cited by 2
Winkler, G. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29237 · Cited by 1
ALFORD, F. P., Rantzau, C., Henriksen, J. E., Egede, M. B., Durck, T. T., Levin, K., & Beck‐Nielsen, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1644 · Cited by 1
Adams, E., Genter, P. M., Keefe, E., Sandow, K., Gray, V., Rotter, J. I., Chen, Y.-D. I., & Ipp, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.010 · Cited by 1
Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes
Saito, R., & Harada, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00781-y · Cited by 2
Steroiddiabetes: Risiken, Diagnostik und Handlungsstrategien
Gallwitz, B. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5113-4 · Cited by 1
Svane, M. S., HINDSØ, M. G., Martinussen, C., Dirksen, C., Jørgensen, N. B., Hedbäck, N., Hartmann, B., Kristiansen, V. B., Holst, J. J., Bojsen-Møller, K. N., et al. (2025) · Diabetes · doi:10.2337/db24-1054 · Cited by 1
Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
Yoo, S., Yang, E.-J., & Koh, G. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0105 · Cited by 2
Precision medicine in diabetes - current trends and future directions. Is the future now?
Szczerbiński, Ł., & Florez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00021-6 · Cited by 1
Incretin physiology in health and disease
Meier, J. J., & Nauck, M. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch11 · Cited by 1
Self-citationExploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Reed, J., & Kanamarlapudi, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101966 · Cited by 1
Type 2 Diabetes Mellitus, Metabolic Syndrome, Lipids
Pinhas‐Hamiel, O. (2010) · Yearbook of pediatric endocrinology · doi:10.1159/000320660
Smith, C. C., Cebra, C. K., Heidel, J. R., & Stang, B. V. (2013) · American Journal of Veterinary Research · doi:10.2460/ajvr.74.11.1409 · Cited by 1
Deane, A. M., & Horowitz, M. (2015) · Journal of Intensive Care Medicine · doi:10.1177/0885066613517073
Editorial. Pathophysiology of Type 2 Diabetes: The Long Journey into Present
Mihai, B. M., Lăcătușu, C.-M., Grigorescu, E.-D., & Botnariu, G. E. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0027
Glucose metabolism in the critically ill.
Deane, A. (2012) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 1
Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
Živković, T. B., Marjanović, M., Vuksanović, M., Soldatović, I., Kanlic, D., & Topalov, D. (2016) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1610497z
Rola leków inkretynowych w leczeniu cukrzycy typu 2
Mizerski, G., & Jaroszyński, A. (2011) · Family Medicine & Primary Care Review
Marathe, C. S. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Green, B., & Connolly, L. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.03.005
Once-weekly DPP-4阻害薬:トレラグリプチン:連日製剤からの切り替えと非劣性の検討
村上雅子, 平原直子, 森田浩, & 佐々木茂和 (2017) · 糖尿病 · doi:10.11213/tonyobyo.60.222
Dietary Proanthocyanidin Modulation of Pancreatic β Cells
Pinent, M., González‐Abuín, N., Blay, M., & Ardèvol, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00016-6 · Cited by 3
Quast, D. R., & Nauck, M. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0268-9 · Cited by 1
Self-citationUtilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Diagnosis of Chronic Pancreatitis
Tang, X., Zhao, A., Yu, J. S., Lin, J., Zou, W., Liao, Z., Li, Z., Su, S., Xu, M., Keller, J., et al. (2017) · Springer eBooks · doi:10.1007/978-981-10-4515-8_7
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Metadata
- Authors
- Meier, J. J., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 59
- Issue
- 5
- Pages
- 1117-1125
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857890
- OpenAlex
- W2097621088
- Cited by
- 215
- References
- 72
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 15 · 2018: 8 · 2017: 16 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 27 · 2012: 19
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, enteroinsular axis, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretin secretion, postprandial insulin secretion, beta-cell mass, insulin resistance
- MeSH terms
- Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Models, Biological, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.